Supplement

– Cost Effective Supplements

Piracetam

Quick navigation


What are Piracetam's other names?

  • 2-Oxo-1-pyrrolidine
  • Fezam
  • Memotopril
  • Pyracetam
  • Pyrrolidone acetamide
  • UCB6215

What is Piracetam's recommended dosage?

  • Recommended daily intake: 1,2 - 4,8 g
  • Recommended daily doses: 3

What supplements interact with Piracetam?

No supplements that have a synergystic effect with this one.

What can Piracetam help with?

  • Piracetam for Breath Holding Spells

  • Piracetam for Mild Cognitive Impairment

test
Moderately Positive


A total of 135 patients, 45 in each group, completed the study. Combined therapy was most effective in patients whose baseline performance on memory tests was lowest. The best results were observed with 4.8 g of piracetam, especially when training sessions began after 6 weeks of drug treatment. This result was confirmed by the global impression of the principal investigator.


test
Moderately Positive


Fifty Patients completed the investigation (25 piracetam, 25 placebo). There were no significant statistical differences between the two groups of patients on all measures utilized except for the Clinical Global Evaluation, where 52% of the patients on piracetam showed minimal improvement versus 25% of the placebo group (P less than 0.05).


test
Moderately Positive


The effect of piracetam therapy with different dosages was studied in a double blind trial against placebo on its effect in psychoorganic syndrome of old age. 78 patients (61 females, 17 males) on the average of 73.2 years, showed statistically significant differences between piracetam therapy at a dosage of 3 X 1600 mg per day und placebo after a six week peroral therapy while no statistically significant differences between piracetam therapy at a dosage of 3X800 mg per day and placebo were found.


test
Moderately Positive


The results of the meta-analysis demonstrate a difference between those individuals treated with piracetam and those given placebo, both as significant odds ratio and as a favourable number needed to treat. While there may be problems in meta-analyses and the interpretation of the statistical results, the results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.


test
Moderately Positive


Thirty subjects completed the 1-year study. No improvement occurred in either group, but our results support the hypothesis that long-term administration of high doses of piracetam might slow the progression of cognitive deterioration in patients with AD. The most significant differences concerned the recall of pictures series and recent incident and remote memory. The drug was well-tolerated.



What is Piracetam used for?

  • Piracetam for Mental health

test
Highly Positive


Complete blood count, biochemical profile, and urine analysis taken before and after treatment revealed no change from beginning to end and no difference between the 2 groups. It is suggested that piracetam is a safe and effective drug, with an incidence of side effects no different from that of placebo, for the treatment of breath-holding spells.


test
Highly Positive


In conclusion, piracetam is a safe and effective drug for the treatment of breath-holding spells in children.


test
Highly Positive


Piracetam is an effective prophylactic treatment for severe BHS.


test
Moderately Positive


A total of 135 patients, 45 in each group, completed the study. Combined therapy was most effective in patients whose baseline performance on memory tests was lowest. The best results were observed with 4.8 g of piracetam, especially when training sessions began after 6 weeks of drug treatment. This result was confirmed by the global impression of the principal investigator.


test
Moderately Positive


Fifty Patients completed the investigation (25 piracetam, 25 placebo). There were no significant statistical differences between the two groups of patients on all measures utilized except for the Clinical Global Evaluation, where 52% of the patients on piracetam showed minimal improvement versus 25% of the placebo group (P less than 0.05).


test
Moderately Positive


The effect of piracetam therapy with different dosages was studied in a double blind trial against placebo on its effect in psychoorganic syndrome of old age. 78 patients (61 females, 17 males) on the average of 73.2 years, showed statistically significant differences between piracetam therapy at a dosage of 3 X 1600 mg per day und placebo after a six week peroral therapy while no statistically significant differences between piracetam therapy at a dosage of 3X800 mg per day and placebo were found.


test
Moderately Positive


The results of the meta-analysis demonstrate a difference between those individuals treated with piracetam and those given placebo, both as significant odds ratio and as a favourable number needed to treat. While there may be problems in meta-analyses and the interpretation of the statistical results, the results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.


test
Moderately Positive


Thirty subjects completed the 1-year study. No improvement occurred in either group, but our results support the hypothesis that long-term administration of high doses of piracetam might slow the progression of cognitive deterioration in patients with AD. The most significant differences concerned the recall of pictures series and recent incident and remote memory. The drug was well-tolerated.


test
Slightly Positive


Nootropyl (Piracetam) a drug reported to facilitate learning in animals was tested for its effect on man by administering it to normal volunteers. The subjects were given 3x4 capsules at 400 mg per day, in a double blind study. Each subject learned series of words presented as stimuli upon a memory drum. No effects were observed after 7 days but after 14 days verbal learning had significantly increased.



What are Piracetam's effects on the body?

  • Piracetam for the Nervous System

Complete blood count, biochemical profile, and urine analysis taken before and after treatment revealed no change from beginning to end and no difference between the 2 groups. It is suggested that piracetam is a safe and effective drug, with an incidence of side effects no different from that of placebo, for the treatment of breath-holding spells.


In conclusion, piracetam is a safe and effective drug for the treatment of breath-holding spells in children.


Piracetam is an effective prophylactic treatment for severe BHS.


A total of 135 patients, 45 in each group, completed the study. Combined therapy was most effective in patients whose baseline performance on memory tests was lowest. The best results were observed with 4.8 g of piracetam, especially when training sessions began after 6 weeks of drug treatment. This result was confirmed by the global impression of the principal investigator.


Fifty Patients completed the investigation (25 piracetam, 25 placebo). There were no significant statistical differences between the two groups of patients on all measures utilized except for the Clinical Global Evaluation, where 52% of the patients on piracetam showed minimal improvement versus 25% of the placebo group (P less than 0.05).


The effect of piracetam therapy with different dosages was studied in a double blind trial against placebo on its effect in psychoorganic syndrome of old age. 78 patients (61 females, 17 males) on the average of 73.2 years, showed statistically significant differences between piracetam therapy at a dosage of 3 X 1600 mg per day und placebo after a six week peroral therapy while no statistically significant differences between piracetam therapy at a dosage of 3X800 mg per day and placebo were found.


The results of the meta-analysis demonstrate a difference between those individuals treated with piracetam and those given placebo, both as significant odds ratio and as a favourable number needed to treat. While there may be problems in meta-analyses and the interpretation of the statistical results, the results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.


Thirty subjects completed the 1-year study. No improvement occurred in either group, but our results support the hypothesis that long-term administration of high doses of piracetam might slow the progression of cognitive deterioration in patients with AD. The most significant differences concerned the recall of pictures series and recent incident and remote memory. The drug was well-tolerated.


Nootropyl (Piracetam) a drug reported to facilitate learning in animals was tested for its effect on man by administering it to normal volunteers. The subjects were given 3x4 capsules at 400 mg per day, in a double blind study. Each subject learned series of words presented as stimuli upon a memory drum. No effects were observed after 7 days but after 14 days verbal learning had significantly increased.


Scroll to top